To top

Category: Uncategorized

14 Oct


Dr. Jürgen Walkenhorst Head of Technology Transfer University of Vienna - Vienna Dr. Jürgen Walkenhorst studied biology/molecular biology in Osnabrück and Aberdeen (UK). After his diploma thesis at the EMBL in Heidelberg, he worked at Genentech, Inc. (USA). He undertook his PhD-thesis at the Max-Planck-Institute for Developmental Biology in Tübingen. He joined Cellzome AG (Heidelberg, now part of GSK) as the first employee where he was instrumental in setting up the company and was later responsible for IP-issues. After a stint in the patent department of Baxter AG in Vienna, he changed to technology transfer. At Austria Wirtschaftsservice GmbH, Vienna, he was managing life science inventions developed at Austrian universities. In 2007 he moved to PROvendis, the central technology transfer agency of the universities of...
Continue reading
4 Oct

Elizabeth Nolan

Elizabeth is responsible for the introduction and growth of a managed consultancy service in University College Dublin. ConsultUCD supports UCD academics to engage in consultancy with external clients.  Elizabeth joined UCD in February 2017. ConsultUCD opened in November 2017 and an additional member of staff joined the team in January 2019. Elizabeth is an experienced management consultant who worked for over 15 years in consultancy in Ireland. As a Director with KPMG Elizabeth worked in the Transformation team where she had responsibility for the People & Change business line. During her career, Elizabeth worked with a variety of clients including large Irish and UK banks, life assurance companies and other financial service companies. Elizabeth also held a senior strategic development role with Ireland’s...
Continue reading
24 Sep

Hynek Kasl

Hynek Kasl is a CTO at XENO Cell Innovations, where he co-leads technical innovation of the synthetic biology line of products, including the development of drug screening platforms and advanced biosensors. Hynek has 8 years of experience in Synthetic Biology and was a founding member of the first Czech iGEM team. Hynek is driven by unexpected solutions provided by his truly interdisciplinary intuition developed through persistent work at the intersection of bioengineering, mathematics, and physics. His approach involves foundational development of ideas using rigorous mathematical analysis backed by experimental evidence....
Continue reading
10 Sep

Siegfried Bialojan

Dr. Siegfried Bialojan studied Biology and Human Medicine at the University of Heidelberg. He received his PhD in Molecular Genetics. After a Post-Doc-period at the German Cancer Center in Heidelberg (1985-1987; focus on cell biology) he joined the pharmaceutical industry and worked for 14 years in various R&D functions at BASF Pharma/Knoll, Abbott. In 2001 he joined EY to establish their Life Science Practice. He built EY´s global Life Science database and was responsible for global data collection and industry knowledge feeding into EY global Thought Leadership publications. Today he is a Director at the EY Life Science Center Mannheim and is responsible for coordination of activities in the biotech sub sector at EY Germany. In this role he also authors...
Continue reading
20 Aug


Robert is the head of the InnCubator, the entrepreneurship centre of the University of Innsbruck and the Economic Chamber of Tyrol. Together with his colleagues he conceptualised the incubator, teaches the basics of entrepreneurship and innovation and supports startups on a daily basis. As interface between the Economic Chamber of Tyrol, the University of Innsbruck and the startups, he facilitates the access to the expert knowledge and the innovation network and fosters collaborative thinking. As part of the research team Innovation and Entrepreneurship of the University of Innsbruck his research focuses on open innovation, crowdsourcing, co-creation and online communities. The underlying dynamics and interaction behaviours of users of these online communities are of his special interest. Robert further looks at new use cases of...
Continue reading
14 Aug

Julie Edwards

Currently a member of Boehringer Ingelheim’s Business Development & Licensing Team, based in Germany, Julie is responsible for leading contract negotiations and managing strategic alliances that support the scientific and business development objectives of the Innovation Unit at Boehringer Ingelheim. In her current role and throughout her career, Julie has proactively and effectively cooperated with key stakeholders in the life sciences ecosystem, from both the private and public sectors, driving the establishment of strategic alliances and partnerships to progress innovative science towards application. Prior to joining Contracts and Alliance Management (CAM), Julie was the Head of Research Beyond Borders (RBB) Project Office and Strategic Partnering at Boehringer Ingelheim, where she fostered the development and implementation of new science project proposals and their...
Continue reading
22 Jul

Daniel Georgiev

Daniel Georgiev co-founded XENO Cell Innovations in 2016 to make diagnostic and bioengineering technologies that compute. XENO BIOLOGIC devices supplant large instrumentation and lab personnel by gathering and processing information in the same sample volume. Daniel received a PhD in Systems and control theory and a MSc in Applied mathematics from the University of Michigan. Following a postdoc in the Klavins Lab, University of Washington, and a brief entrepreneurial sidestep, he founded the first regional synthetic biology laboratory that spawned the 2015 iGEM runner-up team. His research focuses on defining system principles in specific bioengineering contexts....
Continue reading
19 Jun

Karlheinz Schmelig

Karlheinz Schmelig is a Managing Partner at Creathor Ventures focusing on life sciences and healthtech investments. He has a broad background in private equity and venture capital and has been working in the industry for nearly 20 years. Before joining Creathor, Karlheinz worked as an investment director at 3i Group plc and before that as an investment manager at the Technologieholding VC GmbH. Prior to his venture capital career Karlheinz worked successfully for over ten years in a number of global management positions in the healthcare industry. He spent seven of these years in the US at Boehringer Mannheim and F. Hoffmann-La Roche, where he worked in global business development and marketing roles. Karlheinz studied business in Mannheim and received a Master of Business Administration (MBA) from the Kelly School of Business at Indiana University. He is also...
Continue reading
19 Jun

Jaromír Zahrádka

Jaromír Zahrádka is Chief Executive Officer and co-founder of i&i Prague, a biotech incubator and investment company owned by The Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic, v.v.i. (IOCB) in Prague, Czech Republic. IOCB Prague, a public research institute, is well known due to antivirotics and peptide drugs. Among others, the HIV therapy blockbuster Tenofovir TM, marketed by Gilead, originated at IOCB Prague.   i&i Prague is accelerating the proof-of-concept stage of projects in the fields of Medtech, Diagnostics and Drug discovery. The company focuses on scalable projects with excellent innovative potential in discovery, pre-seed or seed phase. Since the company is an investment company, it is able to support projects with pre-seed and seed investment and invite further co-investors to participate.   In total, more than 15 projects are...
Continue reading